Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches.
Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.
Del Toro
Gustavo
G
Division of Pediatric Hematology, Columbia University, 180 Fort Washington Avenue, New York, NY 10032, USA.
Morris
Erin
E
Cairo
Mitchell S
MS
D003937:Diagnosis, Differential; D006801:Humans; D009369:Neoplasms / Q000150:complications; D009626:Terminology as Topic; D015275:Tumor Lysis Syndrome / Q000145:classification* / Q000188:drug therapy* / Q000503:physiopathology; D014503:Urate Oxidase / Q000627:therapeutic use*
C469709:rasburicase; D014503:Urate Oxidase